Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 309

1.

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.

Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M.

Hum Mutat. 2007 Jun;28(6):622-9.

PMID:
17311302
[PubMed - indexed for MEDLINE]
2.

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.

Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M.

Oncogene. 2007 Apr 2;26(15):2157-65. Review.

PMID:
17401424
[PubMed - indexed for MEDLINE]
3.

The IARC TP53 database: new online mutation analysis and recommendations to users.

Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P.

Hum Mutat. 2002 Jun;19(6):607-14.

PMID:
12007217
[PubMed - indexed for MEDLINE]
4.

Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.

Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA.

Cancer Res. 2003 Oct 15;63(20):6643-50.

PMID:
14583457
[PubMed - indexed for MEDLINE]
Free Article
5.

Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations.

Soussi T, Kato S, Levy PP, Ishioka C.

Hum Mutat. 2005 Jan;25(1):6-17.

PMID:
15580553
[PubMed - indexed for MEDLINE]
6.

Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes.

Monti P, Perfumo C, Bisio A, Ciribilli Y, Menichini P, Russo D, Umbach DM, Resnick MA, Inga A, Fronza G.

Mol Cancer Res. 2011 Mar;9(3):271-9. doi: 10.1158/1541-7786.MCR-10-0496. Epub 2011 Feb 22.

PMID:
21343334
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.

Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J.

Cancer Res. 2009 Apr 15;69(8):3625-33. doi: 10.1158/0008-5472.CAN-08-3426. Epub 2009 Mar 31.

PMID:
19336573
[PubMed - indexed for MEDLINE]
Free Article
8.

Transcriptional functionality of germ line p53 mutants influences cancer phenotype.

Monti P, Ciribilli Y, Jordan J, Menichini P, Umbach DM, Resnick MA, Luzzatto L, Inga A, Fronza G.

Clin Cancer Res. 2007 Jul 1;13(13):3789-95.

PMID:
17606709
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The UMD TP53 database and website: update and revisions.

Hamroun D, Kato S, Ishioka C, Claustres M, Béroud C, Soussi T.

Hum Mutat. 2006 Jan;27(1):14-20.

PMID:
16278824
[PubMed - indexed for MEDLINE]
10.

Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.

Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, Tricker KJ, Varley JM.

Oncogene. 1998 Sep 3;17(9):1061-8.

PMID:
9764816
[PubMed - indexed for MEDLINE]
Free Article
11.

Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellations.

Mathe E, Olivier M, Kato S, Ishioka C, Vaisman I, Hainaut P.

Hum Mutat. 2006 Feb;27(2):163-72.

PMID:
16395672
[PubMed - indexed for MEDLINE]
12.

The UMD-p53 database: new mutations and analysis tools.

Béroud C, Soussi T.

Hum Mutat. 2003 Mar;21(3):176-81. Review.

PMID:
12619103
[PubMed - indexed for MEDLINE]
13.

Loss of TP53-DNA interaction induced by p.C135R in lung cancer.

Aranda M, Gonzalez-Nilo F, Riadi G, Díaz V, Perez J, Martel G, Hainaut P, Mimbacas A.

Oncol Rep. 2007 Nov;18(5):1213-7.

PMID:
17914575
[PubMed - indexed for MEDLINE]
14.

DNA sequence profile of TP53 gene mutations in childhood B-cell non-Hodgkin's lymphomas: prognostic implications.

Klumb CE, Furtado DR, de Resende LM, Carriço MK, Coelho AM, de Meis E, Maia RC, Rumjanek FD.

Eur J Haematol. 2003 Aug;71(2):81-90.

PMID:
12890146
[PubMed - indexed for MEDLINE]
15.

Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.

Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P, Hrstka R, Janotova P, Radina M, Lane DP, Coates PJ, Vojtesek B.

J Pathol. 2005 Nov;207(3):251-9.

PMID:
16161005
[PubMed - indexed for MEDLINE]
16.

p53 from basic research to clinical applications.

Tominaga O, Hamelin R, Remvikos Y, Salmon RJ, Thomas G.

Crit Rev Oncog. 1992;3(3):257-82. Review.

PMID:
1616957
[PubMed - indexed for MEDLINE]
17.

Limited importance of the dominant-negative effect of TP53 missense mutations.

Stoczynska-Fidelus E, Szybka M, Piaskowski S, Bienkowski M, Hulas-Bigoszewska K, Banaszczyk M, Zawlik I, Jesionek-Kupnicka D, Kordek R, Liberski PP, Rieske P.

BMC Cancer. 2011 Jun 13;11:243. doi: 10.1186/1471-2407-11-243.

PMID:
21668955
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

[TP53 mutations and molecular epidemiology].

Otsuka K, Ishioka C.

Gan To Kagaku Ryoho. 2007 May;34(5):683-9. Review. Japanese.

PMID:
17496437
[PubMed - indexed for MEDLINE]
19.

Predicting the oncogenicity of missense mutations reported in the International Agency for Cancer Research (IARC) mutation database on p53.

Gorlov IP, Gorlova OY, Amos CI.

Hum Mutat. 2005 Nov;26(5):446-54.

PMID:
16173033
[PubMed - indexed for MEDLINE]
20.

Transcriptional properties of feline p53 and its tumour-associated mutants: a yeast-based approach.

Cardellino U, Ciribilli Y, Andreotti V, Modesto P, Menichini P, Fronza G, Pellegrino C, Inga A.

Mutagenesis. 2007 Nov;22(6):417-23. Epub 2007 Oct 18.

PMID:
17947339
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk